Claritas Pharmaceuticals and CMAX Clinical Research have signed an agreement to conduct a Phase 1 clinical study of R-107. The clinical study is to evaluate the pharmacokinetics and
Johnson & Johnson (J&J) will resume Covid-19 vaccine roll-out in Europe following the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), which confirmed the overall benefit-risk profile
The second indication of Sarclisa (isatuximab) for the treatment of adult patients with relapsed multiple myeloma, was approved by the European Commission (EC). This second approval of Sarclisa
The US Federal trade Commission review has granted clearance for AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals, achieving an important milestone in the completion process. The clearance grant follows
GlaxoSmithKline and Vir Biotechnology have announced the European Medicines Agency (EMA) review of VIR-7831 (GSK4182136) for the early treatment of Covid-19. VIR-7831 is an investigational dual-action SARS-CoV-2 monoclonal
Bristol Myers Squibb has been granted approval by the European Commission (EC) for the use of Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) to treat adults with advanced
Biopharmaceutical company SciNeuro Pharmaceuticals has signed an exclusive license agreement with Eli Lilly and Company for the development and commercialisation of alpha-synuclein targeted antibody therapies in Greater China.
Gilead Sciences has announced the accelerated approval of Trodelvy (or sacituzumab govitecan-hziy) by the US Food and Drug Administration (FDA) in the treatment of locally advanced or metastatic
Integrated pharmaceutical company Dr. Reddy’s Laboratories has secured Emergency Use Authorisation (EUA) from the Drug Controller General of India (DCGI) to import Russia’s Sputnik V vaccine into India.
AT-100 is a new recombinant human protein rhSP-D and is an engineered version of an endogenous protein that reduces inflammation and infection while modulating the immune response to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.